Akiram Therapeutics

📍 Uppsala, Sweden🗓 Founded 2021👥 6 employees💰 Last funded 2022
Biotechnology Research🌐 akiramtherapeutics.se
Website LinkedIn
Akiram Therapeutics is a Swedish biotech company committed to developing innovative and targeted molecular radiotherapy for patients with incurable cancer. Our product combines a radiation component with a proprietary antibody to deliver radioactivity directly to cancer cells while minimizing damage to surrounding healthy tissues. Our research is based on cutting-edge discoveries made at Uppsala University, and our team is composed of experts in radiation sciences, cancer precision medicine, and drug development. At Akiram, our mission is to make targeted molecular radiotherapy widely accessible to cancer patients. We recognize that each patients cancer is unique and requires a personalized approach to treatment. By utilizing state-of-the-art radiopharmaceuticals and precision medicine, we aim to create more effective and personalized treatments for people fighting cancer.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2021
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Sweden
1
Frequently asked questions
Who invested in Akiram Therapeutics?
Akiram Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Akiram Therapeutics last raise funding?
The most recent investment in Akiram Therapeutics recorded on gritt.io was in 2022.
When was Akiram Therapeutics founded?
Akiram Therapeutics was founded in 2021.
What industry is Akiram Therapeutics in?
Akiram Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Akiram Therapeutics based?
Akiram Therapeutics is headquartered in Uppsala, Sweden.